Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HHAT | Q5VTY9 | 4/20 | 0.46 |
| ▸ | LHCGR | P22888 | 2/20 | 0.36 |
| ▸ | NR3C1 | P04150 | 5/20 | 0.36 |
| ▸ | PGR | P06401 | 2/20 | 0.36 |
| ▸ | AR | P10275 | 2/20 | 0.36 |
| ▸ | DRD1 | P21728 | 1/20 | 0.36 |
| ▸ | ESR1 | P03372 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10169781 | 1.00 | HHAT (0.46) | HHATLHCGRNR3C1PGRAR | |
| SCHEMBL490365 | 1.00 | HHAT (0.46) | HHATLHCGRNR3C1PGRAR | |
| SCHEMBL10169784 | 0.83 | SMN1; SMN2 (0.43) | HHAT | |
| SCHEMBL490748 | 0.79 | HHAT (0.33) | HHATKMT2A | |
| SCHEMBL10169794 | 0.79 | HHAT (0.33) | HHATKMT2A | |
| SCHEMBL10169803 | 0.78 | NR3C1 (0.59) | NR3C1PGRARESR1KMT2A | |
| SCHEMBL490408 | 0.70 | HHAT (0.36) | HHATNR3C1PGRARESR1 | |
| SCHEMBL490263 | 0.68 | HTR7 (0.34) | LHCGR | |
| SCHEMBL10169820 | 0.68 | HTR7 (0.34) | LHCGR | |
| SCHEMBL10211128 | 0.68 | HTR7 (0.34) | LHCGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8106046-B2 | Cyclopentathiophene modulators of the glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-01-31 | — | — | US | disclosed |
| EP-2334671-A1 | CYCLOPENTATHIOPHENE MODULATORS OF THE GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-KAPPA B ACTIVITY AND USE THEREOF | Bristol-Myers Squibb Company (US) | 2011-06-22 | — | — | EP | disclosed |
| US-20110105495-A1 | CYCLOPENTATHIOPHENE MODULATORS OF THE GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-kB ACTIVITY AND USE THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2011-05-05 | — | — | US | disclosed |
| WO-2009158380-A1 | CYCLOPENTATHIOPHENE MODULATORS OF THE GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-KAPPA B ACTIVITY AND USE THEREOF | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-12-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110105495-A1 | CYCLOPENTATHIOPHENE MODULATORS OF THE GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-kB ACTIVITY AND USE THEREOF | NFKB2, NFKB1, NFRKB | HHAT 1972/4885LHCGR 2000/4885NR3C1 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.